Insider Buying: AstraZeneca PLC (LON:AZN) Insider Purchases £2,040,600 in Stock

AstraZeneca PLC (LON:AZN) insider Pascal Soriot purchased 20,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of £102.03 ($128.58) per share, for a total transaction of £2,040,600 ($2,571,644.61).

AstraZeneca Stock Down 3.1 %

Shares of AZN stock opened at GBX 9,978 ($125.75) on Monday. AstraZeneca PLC has a one year low of GBX 9,461 ($119.23) and a one year high of £133.88 ($168.72). The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The stock has a fifty day moving average price of £116.38 and a 200 day moving average price of £121.35. The stock has a market cap of £154.66 billion, a P/E ratio of 3,167.62, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on AZN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($138.63) target price on shares of AstraZeneca in a report on Tuesday, September 3rd. Berenberg Bank reaffirmed a “buy” rating and set a £150 ($189.04) target price on shares of AstraZeneca in a research report on Monday, September 2nd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a £140 ($176.43) price objective on shares of AstraZeneca in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of £104.12 ($131.22).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.